Health
Hanvon Technology Launches Groundbreaking Fourth-Generation BP Meter Based on Korotkoff Sound Method
A World Health Organization report highlights that a third of the global adult population suffers from hypertension, with nearly half undiagnosed due to inadequate blood pressure meters, posing significant health risks. BEIJING, Feb. 28, 2024 /PRNewswire/ -- Hanvon Technology Co., Ltd., based in ...
2024-02-29 15:13
1391
Chamlion and 3DRPD Forge Collaboration for Dental 3D Production Center
CHICAGO, Feb. 28, 2024 /PRNewswire/ -- LAB DAY® Chicago 2024 witnessed a new collaboration announcement between Chamlion, a global leader in integrated dental 3D printing solutions, and 3DRPD, a renowned pioneer of 3D printed RPDs. The highlight is to make the announcement of their collaboration ...
2024-02-29 11:46
1330
Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings
- Lunit to unveil four oral presentations and three poster presentations at ECR 2024, highlighting Lunit INSIGHT's expansive capability, ranging from adaptability in different use cases to the potential to replace a human reader in mammography double-reading settings SEOUL, South Korea, Feb. 28...
2024-02-28 22:03
1314
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
Highlights: * Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® * Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R * Confirmation that m...
2024-02-28 20:47
1480
Baird Medical Expands Presence in the United States
FRISCO, Texas, Feb. 28, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced that it is accelerating its expansion inthe United States through ...
2024-02-28 18:00
1456
The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research
HONG KONG, Feb. 28, 2024 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody（cadonilimab）combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer had be...
2024-02-28 17:27
1812
China Jo-Jo Drugstores, Inc. Announces 1-for-20 Reverse Stock Split
HANGZHOU, China, Feb. 27, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (the "Company") (Nasdaq: CJJD), a Cayman Islands exempted company, reported that it expects to implement a 1-for-20 reverse stock split on its ordinary shares ("Ordinary Shares") effective Friday, March 1, 2024, with trad...
2024-02-28 05:05
2552
FDA Grants Fast Track Designation to 9MW2821
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administ...
2024-02-27 22:00
1141
111 Announces Receipt of Withdrawal of Going Private Proposal
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it has received a notice dated Feburary 27, 20...
2024-02-27 21:58
2630
Origin Agritech Announces Breakthrough in Corn Hybrid Development with Wild Corn Gene Integration
BEIJING, Feb. 27, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced a breakthrough development in its commercial corn hybrid offerings. Origin Agritech has successfully integrated a gene from wi...
2024-02-27 21:30
1259
Zhongchao Inc. Announces 1-for-10 Share Consolidation
SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that an extraordinary general meeting of shareholders held onTues...
2024-02-27 21:00
2372
Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development
CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), announced today that it has entered into a collaboration agreement w...
2024-02-27 09:23
1490
BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062
WUXI, China, Feb. 25, 2024 /PRNewswire/ -- BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 clinical study of the novel, oral endothelin A (ETA)-receptor sel...
2024-02-26 22:38
1258
GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.
* Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use inSouth Korea as an adjuvant cell therapy for the treatment of Hepatocellular Carcinoma (HCC) after curative resection and has receivedFDA Orphan Drug Designations (ODDs) for liver, brain...
2024-02-26 21:30
1335
Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") launches MOTPOLY XR™ (lacosamide) extended-release capsules C-V, the first, and only once-daily formulation of lacosamide
PISCATAWAY, N.J., Feb. 26, 2024 /PRNewswire/ -- Aucta Pharmaceuticals, Inc., a private specialty pharmaceutical company focused on niche generic and branded specialty products, today announced the commercial launch of MOTPOLY XR (lacosamide) extended-release capsules C-V (100, 150 and 200 mg). M...
2024-02-26 21:00
1051
TransThera initiates IND-Enabling studies for TT-02332, a novel, highly potent and CNS-penetrating NLRP3 inhibitor
NANJING, China and GAITHURSBURG, Md., Feb. 26, 2024 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLR...
2024-02-26 21:00
1061
J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)
SEOUL, South Korea, Feb. 26, 2024 /PRNewswire/ -- J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Generation EGFR TKI "JIN-A02" for the treatment of NSCLC has been accepted for poster presentation at the upcoming American Association for Cancer Re...
2024-02-26 16:15
1138
Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
WASHINGTON, Feb. 25, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...
2024-02-26 02:00
1316
China Medical University Hospital's Breakthrough: Leg Salvage Against Deadly Arterial Disease. Amputation and Death Rates Plunge from 30% to Below 3%
TAICHUNG, Feb. 24, 2024 /PRNewswire/ -- In winter, cardiovascular diseases are more prevalent, which significantly increase the likelihood of arterial blockage. In addition to increasing the possibility of accompanying myocardial infarction or stroke, seniors should be especially cautious about P...
2024-02-24 21:30
2289
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
HAIKOU, China, Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effectiveWednesday, March 6, 2024, with trading to begin on a split-adjusted basi...
2024-02-24 05:05
4211
Week's Top Stories
Most Reposted
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
[Picked up by 347 media titles]
2024-09-18 11:30
Singapore-based video streaming provider teams up with renowned celebrity platform to provide much-needed boost for brands
[Picked up by 326 media titles]
2024-09-13 17:12
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 315 media titles]
2024-09-16 11:50
NATIONAL ENERGY AWARDS 2024 SHOWCASES MALAYSIA'S COMMITMENT TO ENERGY MANAGEMENT, ENERGY EFFICIENCY AND RENEWABLE ENERGY SOLUTIONS
[Picked up by 289 media titles]
2024-09-13 15:00
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
[Picked up by 284 media titles]
2024-09-14 17:37
Most Read
NATIONAL ENERGY AWARDS 2024 SHOWCASES MALAYSIA'S COMMITMENT TO ENERGY MANAGEMENT, ENERGY EFFICIENCY AND RENEWABLE ENERGY SOLUTIONS
2024-09-13 15:00
13141
Singapore-based video streaming provider teams up with renowned celebrity platform to provide much-needed boost for brands
2024-09-13 17:12
13117
DITO Shares Experience and Future Strategy on 5G SA Core Network Construction
2024-09-13 11:00
8982
MELISHA LIN CROWNED MISS GRAND MALAYSIA 2024
2024-09-13 17:20
8848
